PRISM BioLab (206A) · RiskMitigated
Deterioration in Supply and Demand Due to Sales of Shares Held by Venture Capital Firms
First written in FY2024. 1 of 2 entries say "Mitigated", first in FY2025. Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Deterioration in Supply and Demand from Share Sales by Venture Capital Firms and OthersA theme 62 companies write about · 62 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2019: 2 of 13 companies on the "Worse" side.
20 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 62 companies compared. The sentences above are computed from all 62.Full recordFilings, disclosures and news, newest first
- FY2025MitigatedAnnual report
「As of the end of the fiscal year, venture capital firms and investment partnerships formed by venture capital firms (collectively, “venture capital firms and others”) held 39.88% of our total issued shares.」
The ownership percentage held by venture capital firms and others decreased from 53.38% at the end of the previous fiscal year to 39.88%. - FY2024First statedAnnual report
「As of the end of the fiscal year, venture capital firms and investment partnerships formed by venture capital firms held 53.38% of our total issued shares.」
The company cites the possibility that sales by venture capital firms and others after the listing may affect the share price and market supply and demand.